Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden
Large cell neuroendocrine tumor (LCNEC) of the lung is a rare and aggressive tumor similar to small cell lung cancer (SCLC). Thus, it is often treated similarly to SCLC in the front-line setting with a platinu...
Journal for ImmunoTherapy of Cancer 2017 5:75
Published on: 19 September 2017